I'd add that even if some companies actually have something that works better than typical standard of care, once you get to an actual clinical trial, "standard of care" suddenly moves up a couple of notches compared with the low/mid-level wound care patients normally get. (These patients with non-healing wounds are typically old, poor and diabetic).
So what might be an actual advance in practice turns into nothing in the context of a clinical trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.